EOE

Avangrid Launches New Educational Tool to Simplify Billing for Utility Customers

Retrieved on: 
Friday, March 15, 2024
Education, Utilities, Technology, Oil, Gas, Audio, Video, Energy, Other Education, Electricity, PURA, Tax, The United Illuminating Company, EOE, RG&E, Public policy, Delivery, CMP, Workforce, AGR, RG, UI

This new educational tool will be available for customers of United Illuminating (UI) in Connecticut, Central Maine Power (CMP) in Maine, and New York State Electric & Gas (NYSEG) and Rochester Gas and Electric (RG&E) in New York.

Key Points: 
  • This new educational tool will be available for customers of United Illuminating (UI) in Connecticut, Central Maine Power (CMP) in Maine, and New York State Electric & Gas (NYSEG) and Rochester Gas and Electric (RG&E) in New York.
  • “Customer education is an important facet of how we serve our more than 3.3 million electric and natural gas customers across the northeast,” said Pedro Azagra, Avangrid CEO.
  • “We understand that energy bills can be frustratingly complex with supply and delivery charges, taxes, and public policy costs.
  • In Maine, CMP launched its first-ever animated bill explainer video last year on digital, web, and social platforms.

Eviosys Announces Further Investment in Spain and Portugal, Supporting Market Growth

Retrieved on: 
Sunday, September 17, 2023
Alcochete, EUR, Meat, Steel, EOE, Aluminium

The investment will support additional production, custom printing and expanded logistics capabilities at all the sites, supporting the demand Eviosys customers are seeing in the fish, meat and pet food markets.

Key Points: 
  • The investment will support additional production, custom printing and expanded logistics capabilities at all the sites, supporting the demand Eviosys customers are seeing in the fish, meat and pet food markets.
  • Working closely with partners in Spain and Portugal, Eviosys has seen these highly dynamic markets, rapidly change with consumer trends.
  • As Eviosys continues to grow in 2023, this investment reinforces its leadership in the Iberian Peninsula.
  • In 2023 and beyond, we'll continue to grow with our partners in the region, supporting them in what is a dynamic, fast-moving market, ensuring they can deliver for their customers."

Sanofi/Regeneron's Dupixent Performance in Eosinophilic Esophagitis is Paving the Way for Future Therapies in an Underserved and Growing Market, According to Spherix Global Insights

Retrieved on: 
Tuesday, April 4, 2023
Asthma, Eosinophilic esophagitis, Takeda, Symantec Endpoint Protection, IBD, Gastroenterology, Atopic dermatitis, Polyp (medicine), Launch, AstraZeneca, Alexander Kapp (dermatologist and allergist), Eosinophil, Steroid, Prurigo, Inflammatory bowel disease, Patient, Physician, Risk, EOE, Sinusitis, Growth, BMS, FDA, AD, Disease, Pharmaceutical industry, Dupilumab

EXTON, Pa., April 3, 2023 /PRNewswire/ -- In 2017, Sanofi/Regeneron announced the FDA approval for the first biologic agent to treat atopic dermatitis (AD). The success of that drug, Dupixent (dupilumab), inspired competitors to scramble for a place in the AD market, with the second drug arriving nearly five years later. Sanofi/Regeneron followed with indications in asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis (EoE) and most recently prurigo nodularis.

Key Points: 
  • Sanofi/Regeneron followed with indications in asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis (EoE) and most recently prurigo nodularis.
  • The May 2022 approval of Dupixent for EoE opened the door to another untapped market, with the closest competitor entry likely several years away.
  • Spherix will continue to track the performance of Dupixent's launch for the first eighteen months on the market.
  • Performance to date suggests Dupixent will continue to carve out a commanding ownership of the advanced treatment market in EoE, while also paving the way for future competitors to meet the needs of this underserved, growing market.

Lightwave Logic Provides Fourth Quarter and Fiscal Year 2022 Corporate Update

Retrieved on: 
Thursday, March 2, 2023
Annual report, EOE, PDK, LightWave 3D, Polymer, EO, Conference, ETH Zurich, Patent, Technology transfer, IP, Intellectual property, Internet, ECOC, Logic, Temperature, Silicon, Acquisition, Cryptocurrency, Computer data storage, 3D printing

ENGLEWOOD, Colo., March 2, 2023 /PRNewswire/ -- Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic (EO) polymers to transmit data at higher speeds with less power, today provided a corporate update in conjunction with the filing of its Annual Report on Form 10-K for the quarter and year ended December 31, 2022.

Key Points: 
  • Fourth Quarter 2022 Company Highlights:
    As of December 31, 2022, the company's cash and cash equivalents were $24.1 million, enabling it to finance operations through April 2024.
  • Patent for breakthrough chip-scale packaging technique to enable foundry-level packaging of polymer modulators using chip-scale techniques, enabling simplified high-volume manufacturing through foundry-level packaging.
  • "During the fourth quarter we provided a world-class figure of merit performance for modulators using electro-optical polymers and a plasmonic device design in conjunction with Polariton Technologies.
  • "We continued to see strong validation of our intellectual property (IP) in the fourth quarter with three new patent issuances to strengthen our portfolio.

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis

Retrieved on: 
Monday, January 30, 2023
Royal commission, Inflammation, Immunology, Bruise, Eosinophilic esophagitis, Safety, Conjunctivitis, European Commission, Eosinophilia, Ageing, EC, Esophagus, Medicare Part D, Patient, Union, Arthralgia, Regeneron Pharmaceuticals, DSQ, Choking, Infection, Pain, International development, Pharmaceutical industry, Medical imaging, EU, Sanofi, EOE, Dupilumab, Part

TARRYTOWN, N.Y. and PARIS, Jan. 30, 2023 (GLOBE NEWSWIRE) --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) expanded the marketing authorization for Dupixent® (dupilumab) in the European Union (EU) to treat eosinophilic esophagitis (EoE) in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. With this approval, Dupixent is the first and only targeted medicine specifically indicated to treat EoE in Europe and the U.S.

Key Points: 
  • EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly.
  • With this approval, Dupixent is the first and only targeted medicine specifically indicated to treat EoE in Europe and the U.S.
    “This latest approval establishes Dupixent as the only targeted medicine specifically indicated for eosinophilic esophagitis in the European Union.
  • “Since its first approval, Dupixent has redefined the treatment of certain chronic diseases with underlying type 2 inflammation and is now indicated for five conditions in the European Union.
  • The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved indications.

Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis

Retrieved on: 
Monday, January 30, 2023
Inflammation, Bruise, Eosinophilic esophagitis, Safety, Conjunctivitis, European Commission, Eosinophilia, Ageing, EC, Esophagus, Alveolar soft part sarcoma, Patient, Union, Arthralgia, DSQ, Choking, Infection, Pain, Pharmaceutical industry, Medical imaging, EU, EOE, Dupilumab, Part

EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly.

Key Points: 
  • EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly.
  • Since its first approval, Dupixent has redefined the treatment of certain chronic diseases with underlying type 2 inflammation and is now indicated for five conditions in the European Union.
  • The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved indications.
  • The safety profile through 52 weeks was generally consistent with the safety profile observed at 24 weeks.

Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Allergic Disease

Retrieved on: 
Thursday, January 5, 2023
Immunosuppression, Eosinophilic esophagitis, Allergy, LOS, Patient, Safety, EOE, Immune system, Quality of life, Disease management, Autoimmunity, Allergen, Pharmaceutical industry

“The ability of ’1104 to reduce and reset the inflammatory immune response to common allergens has the potential to provide a long-awaited improvement to disease management with less frequent dosing without immunosuppression,” said Jonathan Rigby, Group Chief Executive Officer of Revolo Biotherapeutics.

Key Points: 
  • “The ability of ’1104 to reduce and reset the inflammatory immune response to common allergens has the potential to provide a long-awaited improvement to disease management with less frequent dosing without immunosuppression,” said Jonathan Rigby, Group Chief Executive Officer of Revolo Biotherapeutics.
  • “Having finalized enrollment and randomization of the trial, we believe we are on track to have topline data in Q2 2023.
  • A medication that provides patients with longer-term symptom relief with less dosing and no immune suppression would be a true improvement.
  • All participants receive six doses of either the investigational drug, ‘1104, or the matched placebo over six visits within a 12-week period.

Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Retrieved on: 
Wednesday, December 21, 2022
The New England Journal of Medicine, Eosinophilic esophagitis, Esophagus, Clinical trial, Rash, Ageing, Food, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Knowledge, European Directive on Traditional Herbal Medicinal Products, Patient, Common, Medicine, Safety, FDA, Inflammation, EOE, EMA, Pharmaceutical industry, Dupilumab

EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly.

Key Points: 
  • EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly.
  • These Phase 3 data have been submitted to the European Medicines Agency (EMA) to support regulatory approval for adults and adolescents with EoE.
  • The EMA’s Committee for Medicinal Products for Human Use recently adopted a positive opinion recommending approval with a final decision expected in the coming months.
  • “The publication of these Phase 3 results in the New England Journal of Medicine reinforces the impact of the clinical trial data.

UNC Health Provider Ushers in First FDA-Approved Medication for Eosinophilic Esophagitis

Retrieved on: 
Thursday, December 22, 2022
Research, General Health, Pharmaceutical, Other Education, Continuing, University, Education, Clinical Trials, Science, FDA, Other Science, Health, The New England Journal of Medicine, Eosinophilic esophagitis, Esophagus, Immunology, Clinical trial, Plasma protein binding, A. Lee Dellon, Communication, Stomach, American College, UNC School of Medicine, Polyp (medicine), Dysphagia, Skin, Dupilumab, Enzyme inhibitor, Inflammation, Multimedia, Food, American College of Allergy, Asthma and Immunology, Irritation, Eosinophil, Patient, Asthma, Infection, Physician, Parasitism, Swelling, FDA, EOE, Regeneron Pharmaceuticals, Sinusitis, Degenerative disease, Colon, Endoscopy, Diagnosis, MPH, Dermatitis, Annals of Allergy, Asthma & Immunology, Biopsy, Electric battery, Pharmaceutical industry, Medical imaging, MD, Allergy, Medicine

Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States.

Key Points: 
  • Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States.
  • View the full release here: https://www.businesswire.com/news/home/20221222005534/en/
    Evan Dellon, MD, MPH, professor of medicine at the UNC School of Medicine and director of the Center for Esophageal Diseases and Swallowing.
  • There is one approved treatment for EoE in several other countries, but it is not available for use in the United States.
  • Dellon believes that initially most doctors will prescribe the therapy for their more severe patients who weren’t responding to prior therapies.

EvoEndo Announces Ambulatory Payment Classification (APC) Reassignments for Flexible Transnasal Esophagogastroduodenoscopy (EGD)

Retrieved on: 
Thursday, December 15, 2022
General Health, Health, Medical Devices, Gastroesophageal reflux disease, Pediatric gastroenterology, Nutrition, CMS, Degenerative disease, Centers for Medicare & Medicaid Services, Italian ship Leonardo (A 5301), VR, Learning, Patient, Biopsy, OPPS, APC, Endoscopy, Eosinophilic esophagitis, EOE, FDA, Malabsorption, EGD, CPT, Virtual reality, Center for Medicare and Medicaid Innovation, Italian ship Ammiraglio Magnaghi (A 5303), Abdominal pain, Columbia University Irving Medical Center, Dysphagia, Physician, TNE, Medicare

We look forward to sharing this new payment alignment with healthcare providers as they consider the clinical and financial value of unsedated transnasal endoscopy, said Heather Underwood, Chief Executive Officer at EvoEndo.

Key Points: 
  • We look forward to sharing this new payment alignment with healthcare providers as they consider the clinical and financial value of unsedated transnasal endoscopy, said Heather Underwood, Chief Executive Officer at EvoEndo.
  • Unsedated transnasal endoscopy with the EvoEndo Single-Use Endoscopy System is designed to reduce preparation and recovery time for upper endoscopy procedures and to eliminate potential risks associated with sedation.
  • The EvoEndo System includes a sterile, single-use, flexible gastroscope designed for unsedated transnasal upper endoscopy, and a small portable video controller.
  • The EvoEndo Comfort Kit includes virtual reality (VR) goggles for patient distraction during the unsedated transnasal endoscopy procedure.